Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling ...

H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Prime Medicine, Inc. (PRME – Research ... by a $55M upfront payment from a strategic partnership with Bristol Myers Squibb. This ...

Prime Medicine, Inc. ( (PRME) ) has released its Q3 earnings. Here is a breakdown of the information Prime Medicine, Inc. presented to its ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Sanofi and Bristol-Myers Squibb have announced they are restructuring ... blood thinner Plavix and hypertension medicine Avapro/Avalide, and the arrival of generic competition in many major ...

All the major pharma companies, including AstraZeneca, Bristol Myers Squibb ... In April 2024, Prime Medicine received the go-ahead from the FDA to initiate a phase I/2 trial with PE-based ...

If you’re on the fence about investing in AbbVie Inc. or Bristol-Myers Squibb Company because you’re not sure ... It also provides facial injectables, plastics and regenerative medicine, body ...

This commitment to persistent innovation and growth strengthens GSK as a prime candidate for investment ... digit earnings-per-share growth. Bristol-Myers Squibb is a global biopharmaceutical ...

As of November 12, 2024, Bristol-Myers Squibb Company had a $119.7 billion market capitalization ... change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and ...

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...